

Translating HbA_{1c} measurements into estimated average glucose values in pregnant women with diabetes

Graham R. Law¹ · Mark S. Gilthorpe² · Anna L. Secher³ · Rosemary Temple⁴ · Rudolf Bilous⁵ · Elisabeth R. Mathiesen³ · Helen R. Murphy⁶ · Eleanor M. Scott²

Received: 14 October 2016 / Accepted: 7 December 2016
© The Author(s) 2017. This article is published with open access at Springerlink.com

Abstract

Aims/hypothesis This study aimed to examine the relationship between average glucose levels, assessed by continuous glucose monitoring (CGM), and HbA_{1c} levels in pregnant women with diabetes to determine whether calculations of standard estimated average glucose (eAG) levels from HbA_{1c} measurements are applicable to pregnant women with diabetes.

Methods CGM data from 117 pregnant women (89 women with type 1 diabetes; 28 women with type 2 diabetes) were analysed. Average glucose levels were calculated from 5–7 day CGM profiles (mean 1275 glucose values per profile) and paired with a corresponding (±1 week) HbA_{1c} measure. In total, 688 average glucose–HbA_{1c} pairs were obtained across pregnancy (mean six pairs per participant). Average glucose level was used as the dependent

variable in a regression model. Covariates were gestational week, study centre and HbA_{1c}.

Results There was a strong association between HbA_{1c} and average glucose values in pregnancy (coefficient 0.67 [95% CI 0.57, 0.78]), i.e. a 1% (11 mmol/mol) difference in HbA_{1c} corresponded to a 0.67 mmol/l difference in average glucose. The random effects model that included gestational week as a curvilinear (quadratic) covariate fitted best, allowing calculation of a pregnancy-specific eAG (PeAG). This showed that an HbA_{1c} of 8.0% (64 mmol/mol) gave a PeAG of 7.4–7.7 mmol/l (depending on gestational week), compared with a standard eAG of 10.2 mmol/l. The PeAG associated with maintaining an HbA_{1c} level of 6.0% (42 mmol/mol) during pregnancy was between 6.4 and 6.7 mmol/l, depending on gestational week.

Conclusions/interpretation The HbA_{1c}–average glucose relationship is altered by pregnancy. Routinely generated standard eAG values do not account for this difference between pregnant and non-pregnant individuals and, thus, should not be used during pregnancy. Instead, the PeAG values deduced in the current study are recommended for antenatal clinical care.

Electronic supplementary material The online version of this article (doi:10.1007/s00125-017-4205-7) contains peer-reviewed but unedited supplementary material, which is available to authorised users.

✉ Eleanor M. Scott
e.m.scott@leeds.ac.uk

- ¹ School of Health and Social Care, University of Lincoln, Lincoln, UK
- ² Division of Epidemiology and Biostatistics, Leeds Institute of Cardiovascular and Metabolic Medicine, Clarendon Way, University of Leeds, Leeds LS2 9JT, UK
- ³ Institute for Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
- ⁴ Elsie Bertram Diabetes Centre, Norfolk and Norwich University Hospital NHS Trust, Norwich, UK
- ⁵ Newcastle University Medicine Malaysia, Johor, Malaysia
- ⁶ Norwich Medical School, University of East Anglia, Norwich, UK

Keywords Average glucose · Continuous glucose monitoring · Estimated average glucose · Gestation · HbA_{1c} · Pregnant · Type 1 diabetes · Type 2 diabetes

Abbreviations

ADAG A1C-Derived Average Glucose study
CGM Continuous glucose monitoring
eAG Estimated average glucose
NICE National Institute for Health and Care Excellence
PeAG Pregnancy-specific estimated average glucose

Introduction

The relationship between HbA_{1c} and average glucose levels has been explored in many studies, most making use of intermittent capillary blood glucose measurements [1–6]. More recently, intensive longitudinal data from continuous glucose monitoring (CGM) have been used to derive a more accurate picture of how average glucose levels compare with HbA_{1c} over time [7–11]. The A1C-Derived Average Glucose (ADAG) study showed a linear association between CGM-measured average glucose and HbA_{1c} levels in non-pregnant adults with type 1 and type 2 diabetes [8]. Following endorsement of the ADAG analysis by the ADA, EASD, International Diabetes Federation (IDF) and International Federation of Clinical Chemists (IFCC) [12], many laboratories now report HbA_{1c} data as a standard estimated average glucose (eAG) alongside the HbA_{1c} result, facilitating greater patient understanding of how daily glucose measurements relate to HbA_{1c} levels.

The ability to accurately assess glucose control is critical in the context of pregnancy in women with diabetes, where achieving tight glucose control has a beneficial impact on maternal–fetal health outcomes. However, HbA_{1c} is considered unreliable for assessing glucose control during pregnancy owing to physiological changes that may be attributed to increased red cell production, shortened red cell life span, reduced red cell affinity for glucose, iron deficiency and iron supplementation [13–17]. This has led to uncertainty over the role of HbA_{1c} for blood glucose assessment in pregnancy [18], with key bodies [19, 20] advising that it should not be used for diagnosing diabetes in pregnancy, and the National Institute for Health and Care Excellence (NICE) in the UK recommending that it should not be routinely used to assess glucose control in pregnancy in women with established diabetes [20]. Furthermore, the relationship between any physiological changes in HbA_{1c} across pregnancy and average glucose levels obtained by CGM is unknown. Despite these limitations, HbA_{1c} is widely used in clinical practice during pregnancy in the UK [21], the USA [22] and internationally [23]. Anecdotal reports also suggest that clinicians and patients are using the standard eAG value, which is reported with HbA_{1c} levels, during pregnancy, despite it being derived from data from non-pregnant adults.

Thus, the aims of this analysis were to: (1) examine the relationship between average glucose levels assessed by CGM and HbA_{1c} levels in pregnancy in women with type 1 and type 2 diabetes; (2) determine if this relationship changes with gestational week during pregnancy; and (3) determine whether the standard eAG calculation that is derived from HbA_{1c} measurements is applicable to pregnant women with diabetes.

Methods

Participants This analysis used data obtained from two previously published studies: one based in the UK (East Anglia) [24] and the second in Denmark (Copenhagen) [25]. Both studies recruited pregnant women with pregestational type 1 or type 2 diabetes to prospective randomised controlled trials that explored the clinical impact of CGM on maternal, fetal and neonatal health outcomes. In the UK, pregnant participants, aged 16–45 years, were recruited from two secondary care diabetes antenatal clinics between 2003 and 2006. In Denmark, pregnant participants, aged 19–43 years, were recruited from one diabetes antenatal clinic between 2009 and 2011. Full details of clinical recruitment procedures (including the exclusion of participants with severe medical or psychological comorbidities) have been described previously [24–26]. A total of 117 participants (49 from England and 68 from Denmark), comprising 89 women with type 1 diabetes and 28 with type 2 diabetes, were included in the present analysis [26].

All participants gave written informed consent. Ethical approval was granted by the Suffolk and Norfolk Local Research Ethics Committee and the Danish National Committee on Biomedical Research Ethics. The Helsinki Declaration and Good Clinical Practice guidelines were adhered to throughout the study.

Antenatal and perinatal care All participants received routine clinical care as per national guidelines. In the UK, this involved antenatal clinic visits every 2–4 weeks, with 4–6 visits including CGM and HbA_{1c} measurements. In Denmark, antenatal clinic visits occurred every 2 weeks, with five study visits at 8, 12, 21, 27 and 33 weeks gestation. These study visits included CGM and HbA_{1c} measurements. CGM profiles were collected over 5–7 days. Both studies used comparable glucose targets to achieve optimum glucose control; in the UK, these were: <5.5 mmol/l before meals, <7.8 mmol/l at 60 min postprandial and <6.7 mmol/l at 120 min postprandial. In Denmark, glucose targets were set at 4.0–6.0 mmol/l before meals, 4.0–8.0 mmol/l at 90 min postprandial and 6.0–8.0 mmol/l before bed.

CGM Continuous glucose monitors were used to record electrochemically measured subcutaneous interstitial glucose concentrations every 5 min, generating 288 measurements per day. Both studies used Medtronic CGM systems (MiniMed, Medtronic, Northridge, CA, USA), with CGM Gold sensors being used in the UK and Guardian REAL-Time CGM with Sof-sensors being used in Denmark. Monitors were calibrated against capillary blood glucose measurements as per the manufacturer's instructions.

HbA_{1c} Blood samples for HbA_{1c} measurements were obtained regularly throughout pregnancy at both centres. Samples

were analysed locally by assays that were DCCT-aligned and from laboratories with National Glycohemoglobin Standardization Program (NGSP) certification.

Statistical analysis Average glucose was calculated as the mean of all glucose values obtained in the 5–7 day CGM profile. The corresponding week of gestation was noted for glucose values and, for analysis, values were paired with the HbA_{1c} values that had been measured within ± 1 week of the CGM profile. Each calculated average glucose value was matched to an individual HbA_{1c}, though women contributed multiple average glucose–HbA_{1c} pairs across their pregnancy. A mixed-effects regression model was therefore used to account for the intra-individual variation with multiple data pairs per woman. In seeking the best-fitting model for the relationship between average glucose and HbA_{1c}, this model included the covariates: gestational age in weeks, HbA_{1c} level and study centre (all centred to their grand mean). The models were explored for linear and curvilinear (squared) relationships, with model fit being assessed using the Akaike information criterion [27], whereby a lower score indicated a better fit of the model. All analyses were conducted in Stata 13, version 13 (StataCorp, College Station, TX, USA).

Results

Relationship between average glucose levels and HbA_{1c} in pregnancy A total of 688 CGM profiles with a mean of 1275 (range 313–2839) glucose measures per profile were obtained for comparison with 688 HbA_{1c} levels. Each woman contributed an average of six average glucose–HbA_{1c} pairs across their pregnancy, at between 8 and 36 weeks gestation.

Fig. 1 shows the association between average glucose and HbA_{1c} values obtained during pregnancy. A linear regression line, with 95% CI, is fitted to the data points ($r^2 = 19.6\%$; average glucose–HbA_{1c} slope = 0.67 [0.57, 0.78]), showing a strong positive association. This implies that, for these women, on average a 1% (11 mmol/mol) difference in HbA_{1c} corresponded to a 0.67 mmol/l difference in their average glucose levels.

Determining the best-fitting model to account for how gestational changes in HbA_{1c} influence the average glucose–HbA_{1c} relationship An intercept-only mixed-effects model was compared with models containing random effects for the slope of the average glucose values in relation to HbA_{1c} levels (Table 1 and electronic supplementary material [ESM] Table 1). As the model containing the random effects of the slope coefficient provided a significant improvement in fit, the random slope was retained. The best-fitting model, with the lowest Akaike information criterion score, was model 5 (see Table 1). This model fitted average glucose to HbA_{1c}, study

centre, gestation in weeks (linear) and gestation in weeks squared (curved). Model 6 examined an interaction between HbA_{1c} and gestation in weeks to determine whether the gradient between average glucose and HbA_{1c} changed during pregnancy; the findings showed that it did not. There was also no interaction between HbA_{1c} and study centre, demonstrating that the relationship between average glucose and HbA_{1c} was consistent across the two datasets.

Deriving a pregnancy-specific eAG Using the best-fitting curvilinear model, Fig. 2 shows the study mean pregnancy-specific eAG (PeAG) levels changing with gestational week for a range of HbA_{1c} levels. As an example, if the HbA_{1c} is measured at 6.0% (42 mmol/mol) during the 12th week of gestation, the PeAG is 6.7 mmol/l, whereas if it is measured at 36 weeks gestation the PeAG is 6.4 mmol/l. To estimate PeAG at any given week during pregnancy, the following equation can be used:


$$\begin{aligned} \text{Glucose (mmol/l)} = & 6.78 + [0.43 \times (\text{HbA}_{1c} [\%] - 6.3)] \\ & + [0.04 \times (\text{Gestation [weeks]} - 21)] \\ & - [0.001 \times (\text{Gestation [weeks]}^2 - 528)] \end{aligned}$$

Comparison of PeAG with the ADAG-calculated eAG The eAG derived using the ADAG formula and that derived by our pregnancy-specific equation for a given value of HbA_{1c} are shown in Table 2. If we were to use the ADAG formula, an HbA_{1c} of 6.0% (42 mmol/mol) would equate to an eAG of 7 mmol/l irrespective of the gestational week, whereas it would equate to a lower PeAG (between 6.4 and 6.7 mmol/l depending on gestational week) using our pregnancy-specific equation. This difference is more pronounced at higher levels of HbA_{1c}, where an HbA_{1c} of 8.0% (64 mmol/mol) equates to a PeAG of 7.7 mmol/l (at 12 weeks gestation and a PeAG of 7.4 mmol/l at 36 weeks gestation but, in contrast, using the ADAG formula, the same HbA_{1c} value would equate to an eAG of 10.2 mmol/l throughout gestation [8].

Discussion

This is the first study to examine the relationship between average glucose levels obtained by CGM and HbA_{1c} levels during pregnancy in women with diabetes. Our analysis demonstrates a positive linear relationship between average glucose and HbA_{1c} levels, but the slope is shallower than that reported in non-pregnant adults [8]. This validates the use of HbA_{1c} to represent average glucose levels during pregnancy, but suggests that a change in HbA_{1c} during pregnancy reflects a smaller change in average glucose than that assumed using the ADAG model [8, 12]. In addition, while we have shown that the relationship between average glucose and HbA_{1c} is

Fig. 1 Average glucose against HbA_{1c} in diabetes. A graph showing average glucose vs HbA_{1c} with a linear fit and 95% CI. White circles, women with type 1 diabetes; black circles, women with type 2 diabetes. To convert values for HbA_{1c} in % into mmol/mol, subtract 2.15 and multiply by 10.929



stable during pregnancy, the absolute mean eAG varies with gestational week. Consequently, HbA_{1c} in pregnancy is associated with a lower eAG than that calculated by ADAG and this difference becomes more marked later in pregnancy. This means that the standard eAG reported with HbA_{1c} is not representative of average glucose levels in pregnancy and should not be used for assessing glucose control in pregnancy. We provide an alternative pregnancy-specific calculation for PeAG based on the observed relationship of HbA_{1c} and average glucose during pregnancy.

The work of the ADAG team has embedded the translation of eAG from HbA_{1c} into routine clinical practice [8, 12]. However, the ADAG analysis deliberately excluded pregnant

women because of pregnancy-related physiological changes in HbA_{1c} [8] and, as a result, the routinely derived eAG may not be applicable to this population. HbA_{1c} is known to fall with the physiological changes associated with pregnancy, particularly in early and late pregnancy [13–17]. A strength of our study is that average glucose and HbA_{1c} data were obtained on repeated occasions (a mean of six times) in the same woman throughout pregnancy, enabling us to take account of gestational week in our data analysis. This revealed the stability of the average glucose–HbA_{1c} relationship across pregnancy.

While our data confirm that a positive association exists between average glucose and HbA_{1c}, the slope of the relationship was shallower than that seen in non-pregnant adults

Table 1 Comparison of an intercept-only mixed-effects model with models containing random effects to determine the best-fitting model to account for how gestational changes in HbA_{1c} influence the average glucose–HbA_{1c} relationship

Model	AIC	Fixed effects	Intercept	HbA _{1c}	Other covariates
1	1911.58	Intercept only	6.88 (6.70, 7.05)		
2	1762.65	+ HbA _{1c}	6.84 (6.69, 7.00)	0.57 (0.37, 0.77)	
3	1759.12	+ HbA _{1c}	6.79 (6.63, 6.95)	0.55 (0.35, 0.75)	−0.39 (−0.70, −0.08)
4	1753.49	+ Centre	6.77 (6.61, 6.93)	0.43 (0.22, 0.64)	−0.43 (−0.75, −0.12)
		+ Centre			−0.01 (−0.02, −0.00)
5	1750.17	+ Gestation	6.78 (6.62, 6.94)	0.50 (0.28, 0.72)	−0.39 (−0.70, −0.07)
		+ Centre			0.04 (−0.01, 0.08)
		+ Gestation			−0.001 (−0.002, −0.000)
		+ Gestation ²			
6	1752.15	+ HbA _{1c}	6.78 (6.62, 6.94)	0.50 (0.28, 0.72)	−0.39 (−0.70, −0.07)
		+ Centre			0.03 (−0.01, 0.08)
		+ Gestation			−0.001 (−0.002, −0.000)
		+ Gestation ²			
		+ HbA _{1c} × Gestation			0.00 (−0.01, 0.02)

Data shown as regression coefficient (95% CI)

The mixed-effects models were fit between average glucose as the outcome and explanatory variables, using time nested within each mother

AIC, Akaike information criterion




Fig. 2 Changes in PeAG during gestation calculated for a range of HbA_{1c} using the best-fitting model. Long dash, 5.0% (31 mmol/mol) HbA_{1c}; dash/dot, 6.0% (42 mmol/mol) HbA_{1c}; solid line, 7.0% (53 mmol/mol) HbA_{1c}; short dash, 8.0% (64 mmol/mol) HbA_{1c}

[7–9], and this gradient remained stable during the last two trimesters of pregnancy. For example, previous data indicate that a 1% (11 mmol/mol) difference in HbA_{1c} is equivalent to a 1.0–2.0 mmol/l difference in average glucose [7–9, 11], whereas our data show that in pregnancy a much smaller difference in average glucose, 0.67 mmol/l, equates to a 1% (11 mmol/mol) difference in HbA_{1c}. This suggests that a change in HbA_{1c} during pregnancy reflects a smaller change in average glucose compared with that seen outside of pregnancy.

Having established that the gradient between the average glucose–HbA_{1c} relationship is stable from the first trimester in pregnancy, there are nevertheless challenges when translating HbA_{1c} levels to eAG values, given the physiological changes that occur in pregnancy. The implication of a fall in HbA_{1c} or average glucose levels as pregnancy progresses means that any fluctuations in either become more sensitive to the gradient relationship. We have shown that gestational week is an important factor to account for when calculating an eAG from the average glucose–HbA_{1c} relationship during pregnancy, since mean levels of average glucose vary throughout pregnancy. Using our best-fitting model, the HbA_{1c} during pregnancy translates to a PeAG that is of a magnitude of 0.5–2.8 mmol/l difference compared with the eAG obtained using the ADAG formula that laboratories report [8, 12], and this difference is more pronounced at higher levels of HbA_{1c} (Table 2). This means that pregnant women and their

clinicians could be misled by the standard eAG readings currently generated for laboratory reports and by automated online calculators. Furthermore, many glucose-monitoring devices generate an estimated HbA_{1c} from average glucose data. It is likely that this HbA_{1c} estimation is currently based on the ADAG formula, which may also be unintentionally misleading during pregnancy.

We consider that our analysis performed in pregnant women builds substantially on the ADAG team's work. It is important, however, to note that while there are similarities, there are also several differences between our analysis and that of the ADAG. In contrast to the prospectively designed ADAG study [8], ours and other studies [9, 11] were pragmatic and made use of existing clinical data obtained from other studies. Compared with the ADAG study, which used 507 participants, of whom 427 had diabetes [8], our study is relatively small and we recognise that a larger study would help to improve the precision of our model to more confidently ascertain the relationship between average glucose and HbA_{1c} levels. In addition, the ADAG study included participants with a greater range of HbA_{1c} levels, including many with far higher HbA_{1c} values than the participants in our study.

The ADAG study paired the average glucose measures obtained by intermittent CGM readings taken for 2–3 days, every 4 weeks over a period of 3 months (giving ~2500 glucose values per participant) to an HbA_{1c} taken at the end of the 3 months measurement period [8], resulting in one average glucose–HbA_{1c} pair per participant. In contrast, to address the complex issue of gestational physiological changes in HbA_{1c}, the average glucose values obtained in our study were derived from an individual CGM session of 5–7 days, (giving a mean of 1275 glucose values), and were compared with an HbA_{1c} value taken within ± 1 week of the CGM profile, yielding a mean of six average glucose–HbA_{1c} pairs per participant. Previous small studies conducted in the 1980s used capillary blood glucose testing to calculate average glucose in pregnancy and showed a strong positive correlation between HbA_{1c} and the preceding 8–12 weeks' average glucose values [28, 29]. We obtained the strongest relationship between average glucose and HbA_{1c} when both were measured within a few weeks of each other (ESM Table 2), suggesting that in pregnancy an HbA_{1c} value is more reflective of current average glucose readings (obtained by CGM) than those obtained

Table 2 Comparison of eAG values calculated from varying levels of HbA_{1c} using the ADAG calculation, vs the PeAG calculation.

HbA _{1c} % (mmol/mol)	ADAG eAG mmol/l	PeAG mmol/l		
		12 weeks gestation	24 weeks gestation	36 weeks gestation
5.0 (31)	5.4	6.2	6.2	5.9
6.0 (42)	7.0	6.7	6.7	6.4
7.0 (53)	8.6	7.2	7.2	6.9
8.0 (64)	10.2	7.7	7.7	7.4

over the preceding 3 months. Anecdotally, it is very common to see dramatic reductions in HbA_{1c} over very short periods of time (<4 weeks) at the start of pregnancy as women are motivated to rapidly optimise their glucose control upon finding out that they are pregnant; this may account for this more proximal relationship.

The ADAG study chose to weight their analysis with intermittent daytime capillary glucose readings but we did not. The rationale for weighting their analysis is unclear as: (1) CGM is already calibrated with regular capillary glucose readings; and (2) intermittent capillary glucose readings do not represent the ‘true’ average glucose value across the 24 h day since they are intermittent, ignore overnight glucose levels and may be skewed by postprandial glucose excursions. Since the ADAG analysis found that the average glucose–HbA_{1c} relationship was unchanged if only CGM readings were used for analysis, we decided to adopt this approach and not weight our analysis [8].

Our data have some further limitations; the women in our study were predominantly white European, which may limit applicability of our findings to women from other cultures and backgrounds. Our analysis did not include any women with gestational diabetes, so care needs to be taken with regard to its applicability in this context. We did not have data on haematocrit levels or iron deficiency/supplementation in our participants but, given that these are factors in the physiological changes of HbA_{1c} during pregnancy, this information might be useful to include in any future analysis of HbA_{1c} and average glucose levels in pregnancy.

We know from population-based studies that HbA_{1c} in pregnancy is a useful guide for pregnancy outcome and risk stratification [30] and is recommended by NICE for this purpose [20]. The ADA recommends regular assessment of glucose control during pregnancy, using monthly HbA_{1c}, to maintain a level of 6.0–6.5% (42–48 mmol/mol) [22]; however, NICE was unable to make this recommendation because of a lack of data for validation of the relationship between HbA_{1c} to average glucose levels during pregnancy [20]. Our current analysis now provides this validation.

CGM is increasingly being used in clinical practice. The average glucose level calculated from the intensive longitudinal glucose data on these devices is far superior to that obtained by capillary glucose meters. Increasing the accessibility and use of CGM as an alternative to capillary glucose testing may significantly improve glucose management during pregnancy [24–26]. One of the difficulties of using CGM in pregnancy is determining exactly which aspects of glucose control to target. Targeting weekly PeAG could be a simple way to help women achieve the glucose control necessary to maintain their HbA_{1c} at ‘low risk’ levels across pregnancy. Our data would suggest that maintaining a PeAG of 6.4–6.7 mmol/l throughout pregnancy should achieve an HbA_{1c} of 6.0% (42 mmol/mol), which is necessary for reducing the risk of adverse pregnancy outcomes.

In summary, HbA_{1c} can be translated to eAG values in pregnant women with diabetes, but these are not the same as those commonly reported. Therefore, pregnancy-specific values, PeAG, are recommended for use in antenatal clinical care.

Data availability Data from the English study is available on request from HRM (Helen.Murphy@uae.ac.uk). Data from the Danish study is available on request from ERM (elisabeth.reinhardt.mathiesen@regionh.dk)

Funding This analysis received no source of external funding. The original UK study [24] was an investigator-initiated study funded by the Ipswich Diabetes Centre Charity Research Fund. The study equipment (six CGMS Gold monitors and 300 sensors) was donated free of charge by Medtronic. Data collection, statistical analyses and data interpretation were performed independently of all study funders. GRL, MSG and EMS were funded by HEFCE. HRM is funded by the National Institute for Health Research (Career Development Fellowship, CDF-2013-06-035).

The original Danish study [25] was also an investigator-driven study designed by the authors, mainly sponsored by independent sources. ALS received financial support from the European Foundation for the Study of Diabetes and LifeScan, Rigshospitalet’s Research Foundation, The Capital Region of Denmark, The Medical Faculty Foundation of Copenhagen University, Aase and Ejnar Danielsen’s Foundation, Master joiner Sophus Jacobsen and wife Astrid Jacobsen’s Foundation. ERM received financial support from the Novo Nordisk Foundation and has nothing to declare. Medtronic supplied the Danish study with real-time CGM monitors and links and glucose sensors were offered at a reduced price, but the company had no influence on study design, handling of data or writing of the manuscript.

Duality of interest The authors confirm that there is no duality of interest associated with this manuscript.

Contribution statement RB, EMS and HRM conceived and designed the study. HRM and RT designed the English study and contributed to data acquisition. ERM and ALS designed the Danish study and contributed to data acquisition. GRL, MSG and EMS analysed the data. All authors interpreted the data. GRL and EMS drafted the initial paper prior to it being critically revised by all authors. All authors approved the final version of the article to be published. GRL had full access to all of the data in the study, HRM to the English data and ERM to the Danish data. GRL, HRM and ERM are the guarantors of this work and take responsibility for the integrity of the data and the accuracy of the data analysis.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A (1976) Correlation of glucose regulation and hemoglobin A_{1c} in diabetes mellitus. *N Engl J Med* 295:417–420

2. Nathan DM, Singer DE, Hurxthal K, Goodson JD (1984) The clinical information value of the glycosylated haemoglobin assay. *N Engl J Med* 310:341–346
3. Rohlfing CL, Wiedmeyer HM, Little R, England JD, Tennill A, Goldstein DE (2002) Defining the relationship between plasma glucose and HbA_{1c} in the diabetes control and complications trial. *Diabetes Care* 25:275–278
4. Murata GH, Hoffman RM, Duckworth WC, Wendel CS, Shah JH (2004) Contributions of weekly mean blood glucose values to haemoglobin A_{1c} in insulin-treated type 2 diabetes: the Diabetes Outcomes in Veterans Study (DOVES). *Am J Med Sci* 327:319–323
5. Tahara Y, Shima K (1993) The response of GHb to stepwise plasma glucose over time in diabetic patients. *Diabetes Care* 9:1313–1314
6. Paisley RB, MacFarlane DG, Sgeriff RJ, Hartog M, Slade RR, White DA (1980) The relationship between blood glycosylated haemoglobin and home capillary blood glucose levels in diabetics. *Diabetologia* 19:31–34
7. Nathan DM, Turgeon H, Regan S (2007) Relationship between glycosylated hemoglobin levels and mean glucose levels over time. *Diabetologia* 50:2239–2244
8. Nathan DM, Kuenen J, Borg R, Zheng H, Schonendorf D, Heine RJ for the A1c-Derived Average Glucose (ADAG) Study Group (2008) Translating the A_{1c} assay into estimated average glucose values. *Diabetes Care* 31:1473–1478
9. Munshi MN, Segal AR, Slyne C, Samur AA, Brooks KM, Horton ES (2015) Shortfalls in the use of HbA_{1c}-derived eAG in older adults with diabetes. *Diabetes Res Clin Pract* 110:60–65
10. Borg R, Kuenen JC, Carstensen B et al (2011) HbA_{1c} and mean glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: the A_{1c}-Derived Average Glucose (ADAG) study. *Diabetologia* 54:69–72
11. DirectNet Study Group (2008) Relationship of A_{1c} to glucose concentrations in children with type 1 diabetes: assessments by high frequency glucose determination by sensors. *Diabetes Care* 31:381–385
12. Consensus Committee (2007) Consensus statement on the worldwide standardization of the haemoglobin A_{1c} measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. *Diabetes Care* 30:2399–2400
13. Nielsen LR, Ekblom P, Damm P et al (2004) HbA_{1c} levels are significantly lower in early and late pregnancy. *Diabetes Care* 27:1200–1201
14. Herranz L, Saez-De-Ibarra I, Grande C, Pallardo LF (2007) Non-glycemic-dependent reduction of late pregnancy A_{1c} levels in women with type 1 diabetes. *Diabetes Care* 30:1579–1580
15. Mortensen HB, Christophersen C (1983) Glucosylation of human haemoglobin A in red blood cells studied in vivo: kinetics of the formation and dissociation of haemoglobin A_{1c}. *Clin Chem Acta* 134:317–326
16. Sinha N, Mishra TK, Singh T, Gupta N (2012) Effect of iron deficiency anaemia on hemoglobin A_{1c} levels. *Ann Lab Med* 32:17–22
17. Phelps RL, Honig GR, Green D, Metzger BE, Frederiksen MC, Freinkel N (1983) Biphasic changes in HbA_{1c} concentrations during normal human pregnancy. *Am J Obstet Gynecol* 147:651–653
18. Hughes RC, Rowan J, Florkowski CM (2016) Is there a role for HbA_{1c} in pregnancy? *Curr Diab Rep* 16:5
19. World Health Organization (2011) Use of glycosylated haemoglobin (HbA_{1c}) in the diagnosis of diabetes mellitus. Abbreviated report of a WHO consultation 2011. Available from www.who.int/diabetes/publications/report-hba1c_2011.pdf. Accessed 5 Aug 2016
20. NICE (2015) Diabetes in pregnancy: management from preconception to the postnatal period. Available from www.nice.org.uk/guidance/ng3. Accessed 5 Aug 2016
21. Murphy HR, Bell R, Holt RI et al (2013) The National Pregnancy in Diabetes Audit: measuring the quality of diabetes pregnancy care. *Diabet Med* 30:1014–1016
22. American Diabetes Association (2015) Management of diabetes in pregnancy. Sec. 12. *Diabetes Care* 38(Suppl 1):S77–S79
23. Persson M, Norman M, Hanson U (2009) Obstetric and perinatal outcomes in type 1 diabetic pregnancies: a large, population-based study. *Diabetes Care* 32:2005–2009
24. Murphy HR, Rayman G, Lewis K et al (2008) Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial. *BMJ* 337:a1680
25. Secher AL, Ringholm L, Andersen HU, Damm P, Mathiesen ER (2013) The effect of real-time continuous glucose monitoring in pregnant women with diabetes: a randomized controlled trial. *Diabetes Care* 36:1877–1883
26. Law GR, Secher A, Temple R et al (2015) Analysis of continuous glucose monitoring in pregnant women with diabetes: distinct temporal patterns of glucose associated with large-for-gestational-age infants. *Diabetes Care* 38:1319–1325
27. Akaike H (1973) Information theory and an extension of the maximum likelihood principle. In: Petrov, BN, Csáki F (eds) 2nd International Symposium on Information Theory. Akadémiai Kiadó, Budapest, pp 267–281
28. Madsen H, Ditzel J, Hansen P, Hahnemann N, Anderson OP, Kjaergaard JJ (1981) Hemoglobin A_{1c} determinations in diabetic pregnancy. *Diabetes Care* 4:541–546
29. Kjaergaard JJ, Ditzel J (1979) Hemoglobin A_{1c} as an index of long-term blood glucose regulation in diabetic pregnancy. *Diabetes* 28:694–696
30. Maresh MJA, Holmes VA, Patterson CC et al (2015) Glycemic targets in the second and third trimester of pregnancy for women with type 1 diabetes. *Diabetes Care* 38:34–42